RxDoctor Payments DataLook up a doctor →

Roderick Warren, MD

Neurology · Evansville, INNPI 1093719841

Payments from drug & device makers

$296,385in general payments, 2019–2025

Across 1,905 payments — averaging $155.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$61K
  • Lilly USA, LLC$48K
  • Amgen$35K
  • Biogen$35K
  • Eisai Inc.$27K
  • TG Therapeutics, Inc.$17K
  • plus $72K from 54 others

What the payments were for

  • Consulting fees$24,2468%
  • Speaking & faculty fees$227,93477%
  • Grants$880%
  • Travel & lodging$11,0084%
  • Food & beverage$32,51711%
  • Education$5930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)351$61,261
Lilly USA, LLC193$48,236
Amgen(2 entities)77$35,473
Biogen105$35,382
Eisai Inc.79$26,966
TG Therapeutics, Inc.44$16,967
Pfizer70$11,841
Teva Pharmaceuticals USA, Inc.75$11,576
AstraZeneca52$10,295
Biohaven Pharmaceuticals, Inc.28$9,295
Sanofi26$7,150
Biohaven Pharmaceutical Holding Company Ltd.25$5,567
Livanova USA, Inc.30$2,689
EMD Serono, Inc.78$1,691
Novartis87$1,124
Vanda Pharmaceuticals Inc.19$887
UCB, Inc.36$769
Supernus Pharmaceuticals, Inc.63$607
Avanir Pharmaceuticals, Inc.50$526
Catalyst Pharmaceuticals, Inc.20$503
SK Life Science, Inc.22$469
Lundbeck LLC30$463
Neurocrine Biosciences, Inc.24$443
MDD US Operations, LLC27$441
Genentech USA, Inc.25$413
Jazz Pharmaceuticals Inc.13$410
Sunovion Pharmaceuticals Inc.41$398
Neurelis, Inc.22$386
Acadia Pharmaceuticals Inc17$361
CSL Behring13$325
Bristol Myers Squibb24$288
Argenx US, Inc.12$276
Mallinckrodt Hospital Products Inc.10$243
Ceribell, Inc.1$243
Amneal Pharmaceuticals LLC13$238
Johnson & Johnson8$224
Tanabe Pharma America, Inc.9$202
Kyowa Kirin, Inc.11$198
Acorda Therapeutics, Inc11$194
Otsuka America Pharmaceutical, Inc.6$154
Banner Life Sciences, LLC7$149
E.r. Squibb & Sons, L.L.C.4$121
Takeda Pharmaceuticals U.S.A., Inc.4$112
Sumitomo Pharma America, Inc.6$105
Grifols USA, LLC4$91
Upsher-smith Laboratories LLC4$89
Adamas Pharmaceuticals, Inc.4$81
ANI Pharmaceuticals, Inc.3$65
Zyla Life Sciences, Inc.3$51
Shire North American Group Inc2$44
Scilex Pharmaceuticals Inc.2$40
Alnylam Pharmaceuticals Inc.2$34
Ironshore Pharmaceuticals Inc.1$32
Amylyx Pharmaceuticals, Inc.1$31
Merck2$26
Nevro Corp.1$21
Servier Pharmaceuticals LLC1$19
Cycle Pharmaceuticals Inc1$18
Assertio Therapeutics, Inc.1$17
Akcea Therapeutics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296,385 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$159,433
Medicare patients
718
Services billed
5,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab75$699,238
TecfideraDimethyl Fumarate31$279,024
AubagioTeriflunomide28$251,764
AustedoDeutetrabenazine25$144,634
BetaseronInterferon Beta-1b14$136,539
NuplazidPimavanserin Tartrate26$132,550
GilenyaFingolimod Hcl12$124,382
Avonex Pen (4 Pack)Interferon Beta-1a13$108,003
Nurtec OdtRimegepant Sulfate71$107,304
Avonex (4 Pack)Interferon Beta-1a13$103,927
KeppraLevetiracetam40$102,718
CopaxoneGlatiramer Acetate17$100,582
VimpatLacosamide56$98,176
NuedextaDextromethorphan Hbr/Quinidine46$73,586
XcopriCenobamate51$66,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$35,382$382,95144 claims
SanofiAubagio$7,150$251,76428 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$11,576$245,21642 claims
UCB, Inc.Vimpat, Briviact, Neupro$769$155,954105 claims
Acadia Pharmaceuticals IncNuplazid$361$132,55026 claims
NovartisGilenya$1,124$124,38212 claims
AbbVieUbrelvy, Qulipta$61,261$107,87781 claims
PfizerNurtec Odt$11,841$107,30471 claims
Avanir Pharmaceuticals, Inc.Nuedexta$526$73,58646 claims
SK Life Science, Inc.Xcopri$469$66,14351 claims
Sunovion Pharmaceuticals Inc.Aptiom$398$56,62828 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$238$34,099107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.

Other neurology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →